Philip Chambers

Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

Gordon Hutchins, Katie Southward, Kelly Handley et al. · Journal of Clinical Oncology · 2011 · 675 citations · Full text

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Susan D. Richman, Philip Chambers, Faye Elliott et al. · Journal of Clinical Oncology · 2009 · 567 citations

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Sarah Brown, Gary Middleton, Tim Maughan et al. · The Lancet Oncology · 2013 · 388 citations · Full text

<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials

Susan D. Richman, Katie Southward, Philip Chambers et al. · The Journal of Pathology · 2015 · 231 citations · Full text

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

Jon M. Askham, Fiona M. Platt, Philip Chambers et al. · Oncogene · 2009 · 107 citations

Urology, Genitourinary Cancer, Oncogenic Agent +9